Evidence map›Paper›PMID 38362373›Full record

ReviewClinical and experimental vaccine research2024

Current development of therapeutic vaccines for the treatment of chronic infectious diseases.

Pil-Gu Park, Munazza Fatima, Timothy An, Ye-Eun Moon, Seungkyun Woo, Hyewon Youn, Kee-Jong Hong

Open access · diamondAbstract readReview
In one paragraph

Review in Clinical and experimental vaccine research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Repurposing Tumor Cells: A Paradigm Shift in Cell-Based Therapies for Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Pil-Gu ParkDepartment of Microbiology, Gachon University College of Medicine, Incheon, Korea.ORCID https://orcid.org/0000-0002-3024-3439
Munazza FatimaDepartment of Microbiology, Gachon University College of Medicine, Incheon, Korea.ORCID https://orcid.org/0000-0002-1212-9667
Timothy AnLee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Korea.ORCID https://orcid.org/0000-0002-4356-6827
Ye-Eun MoonLee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Korea.ORCID https://orcid.org/0009-0004-5808-1664
Seungkyun WooLee Gil Ya Cancer and Diabetes Institute, Gachon University, Incheon, Korea.ORCID https://orcid.org/0009-0003-3574-8406
Hyewon YounDepartment of Nuclear Medicine, Cancer Imaging Center, Seoul National University Hospital, Seoul, Korea.ORCID https://orcid.org/0000-0003-1006-2689
Kee-Jong HongDepartment of Microbiology, Gachon University College of Medicine, Incheon, Korea.ORCID https://orcid.org/0000-0003-2054-7014
Gachon University · KRSeoul National University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic infectious diseases refer to diseases that require a long period of time from onset to cure or death, the use of therapeutic vaccines has recently emerged to eradicate diseases. Currently, clinical research is underway to develop therapeutic vaccines for chronic infectious diseases based on various vaccine formulations, and the recent success of the messenger RNA vaccine platform and efforts to apply it to therapeutic vaccines are having a positive impact on conquering chronic infectious diseases. However, since research on the development of therapeutic vaccines is still relatively lacking compared to prophylactic vaccines, there is a need to focus more on the development of therapeutic vaccines to overcome threats to human health caused by chronic infectious diseases. In order to accelerate the development of therapeutic vaccines for chronic infectious diseases in the future, it is necessary to establish a clear concept of therapeutic vaccines suitable for the characteristics of each chronic infectious disease, as well as standardize vaccine effectiveness evaluation methods, secure standards/reference materials, and simplify the vaccine approval procedure.

Indexed as

Chronic infectious diseaseClinical trialsTherapeutic vaccine

Identifiers

PMID38362373
PMCPMC10864879
OpenAlexW4392830437

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.